Treatment recommendations for FLT3-Mutated AML. Color code: Blue background with white text: standard of care; green background with red text: investigational approaches. Aza, azacitidine; ELN, European Leukemia Network; Gilt, gilteritinib; IC, intensive chemotherapy; LDAC, low dose cytarabine; ND, newly diagnosed; R/R, relapsed/refractory; Ven, venetoclax.

*Data exist supporting allo-HSCT for all patients with FLT3-ITD-mutated AML, even if they are classified as favorable risk by the 2017 ELN guidelines based on a low ITD allelic ratio and concurrent NPM1 mutation. The updated 2022 ELN guidelines classify all FLT3-ITD-mutated AML as intermediate risk.

**Sorafenib maintenance after allo-HSCT is approved per National Comprehensive Cancer Network guidelines but not commonly used in clinical practice. Sorafenib is only effective against FLT3-ITD mutations, not FLT3-TKD mutations.

Created with BioRender.com.